TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer

Cancer Medicine

Volumn 4, Issue 11, 2015, Pages 1667-1678

  Fujii, Satoshi ^a   Fujihara, Ayano ^a   Natori, Kei ^a   Abe, Anna ^a   Kuboki, Yasutoshi ^a   Higuchi, Youichi ^a   Aizawa, Masaki ^b   Kuwata, Takeshi ^a   Kinoshita, Takahiro ^a   Yasui, Wataru ^c   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NIIGATA CANCER CENTER HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cancer stromal cell; Cancer associated fibroblast; Gastric cancer; Immunohistochemistry; TEM1

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOSIALIN; CD248 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FIBROBLAST; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH SURGERY; TUMOR INVASION; TUMOR VOLUME; ADOLESCENT; ANIMAL; CANCER GRADING; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; STOMACH NEOPLASMS; TUMOR CELL LINE; VERY ELDERLY; XENOGRAFT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; GENE EXPRESSION; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84989806021     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.515     Document Type: Article

References (16)

1. Orimo, A., and R. A. Weinberg . 2006. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5:1597-1601. Review.
2. Rettig, W. J., P. Garin-Chesa, J. H. Healey, S. L. Su, E. A. Jaffe, and L. J. Old . 1992. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA 89:10832-10836.
3. Huang, H. P., C. L. Hong, C. Y. Kao, S. W. Lin, S. R. Lin, H. L. Wu, et al. 2011. Gene targeting and expression analysis of mouse Tem1/endosialin using a lacZ reporter. Gene Expr. Patterns 11:316-326.
4. Bagley, R. G., W. Weber, C. Rouleau, M. Yao, N. Honma, S. Kataoka, et al. 2009. Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int. J. Oncol. 34:619-627.
5. Becker, R., M. C. Lenter, T. Vollkommer, A. M. Boos, D. Pfaff, H. G. Augustin, et al. 2008. Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J. 22:3059-3067.
6. Nanda, A., B. Karim, Z. Peng, G. Liu, W. Qiu, C. Gan, et al. 2006. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc. Natl. Acad. Sci. USA 103:3351-3356.
7. Tomkowicz, B., K. Rybinski, B. Foley, W. Ebel, B. Kline, E. Routhier, et al. 2007. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc. Natl. Acad. Sci. USA 104:17965-17970.
8. Hoshino, A., G. Ishii, T. Ito, K. Aoyagi, Y. Ohtaki, K. Nagai, et al. 2011. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res. 71:4769-4779.
9. Witowski, J., and A. Jörres . 2006. Peritoneal cell culture: fibroblasts. Perit. Dial. Int. 26:292-299.
10. Fujii, S., K. Tokita, N. Wada, K. Ito, C. Yamauchi, Y. Ito, et al. 2011. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30:4118-4128.
11. Fujii, S., K. Ito, Y. Ito, and A. Ochiai . 2008. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 283:17324-17332.
12. MacFadyen, J. R., O. Haworth, D. Roberston, D. Hardie, M. T. Webster, H. Morris, et al. 2005. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett. 579:2569-2575.
13. Christian, S., R. Winkler, I. Helfrich, A. M. Boos, E. Besemfelder, D. Schadendorf, et al. 2008. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am. J. Pathol. 172:486-494.
14. Rouleau, C., M. Curiel, W. Weber, R. Smale, L. Kurtzberg, J. Mascarello, et al. 2008. Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin. Cancer Res. 14:7223-7236.
15. Dolznig, H., N. Schweifer, C. Puri, N. Kraut, W. J. Rettig, D. Kerjaschki, et al. 2005. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 5:10.
16. Rouleau, C., J. Sancho, J. Campos-Rivera, and B. A. Teicher . 2012. Endosialin expression in side populations in human sarcoma cell lines. Oncol. Lett. 3:325-329.